Abstract library

99 results for "Ki 67".
#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada
#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Category: Basic
Presenting Author: MD FRANCESCA SPADA
#2266 Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors
Introduction: Several inflammatory response materials could be used for prediction of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number >400*103/mm3) have been introduced for prognostic scoring system in various cancers.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Raluca Roxana Grigorescu
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1567 Pancreatic Neuroendocrine Tumors: Experience from a Single Institute
Introduction: A dedicated multidisciplinary team is necessary in the management of pancreatic neuroendocrine tumor (pNET).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Andrea Caff
Authors: Caff A, Cordio S, Pellegriti G, Russo M, ...
Keywords: pancreatic, Ki-67
#47 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in Patients with Neuroendocrine Tumors
Introduction: Carcinoid heart disease (CHD) is a known complication of neuroendocrine tumors (NETs), particularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcinoids). CHD is characterized by right heart fibrotic lesions and has traditionally been defined by the degree of valvular involvement, most commonly in the form of tricuspid regurgitation. Right ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor (CCN2) is upregulated in many fibrotic disorders. Increased tumor expression of CCN2 has been shown in patients with small intestinal NETs associated with peritoneal fibrosis. At present, its role in carcinoid heart disease is unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Deidi S Bergestuen
#70 The validity of Ki-67 as a prognostic indicator in patients with appendiceal carcinoid tumor
Introduction: Carcinoid tumors of the appendix are rare and often discovered incidentally through appendectomy. Most are clinically benign but may be associated with metastatic disease. Ki-67, a nuclear protein structurally associated with chromatin, is an excellent marker for measuring cell proliferation and it has been shown to correlate with the outcome in pancreatic and ileocecal carcinoids.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Eric Y Liu
Authors: Liu E, Telem D A, Hwang J, Warner R R P, ...
#97 The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multdisciplinary cancer center
Introduction: The role of Ki-67 in NETs has become increasingly important, especially in light of the current trend in oncology to incorporate pathological molecular characteristics in determining treatment. In North America, Ki-67 is used inconsistently, as there exists some debate in the literature about its predictive value.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Rowsel C, Ingber N, Yang S, ...
#98 Long-term follow-up analysis of lung carcinoid tumors: retrospective monoinstitutional evaluation
Introduction: Detection of prognostic factors of bronchopulmonary carcinoid (BPCs) tumors is complicated due to the rare frequency of this malignancy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Emilio Bajetta
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel